Pharmaceutical manufacturers should feel empowered to lead the charge and improve medication adherence as a way to prevent downstream problems that would impact their organizations.
The healthcare industry is facing a time of great regulatory uncertainty over the next four years under the Trump administration. Industry priorities that many have become accustomed to will be scrutinized and potentially replaced. Regardless of upcoming changes in policy and technology, the U.S. healthcare system must continue to find ways to improve patient outcomes while reducing the costs associated with delivering quality care.
Improving patient outcomes while reducing or managing costs is a problem that must be tackled from many angles, in part by focusing on specific areas of healthcare to identify sustainable solutions both in delivery and long-term impact.
